Literature DB >> 16303180

ELF4 is fused to ERG in a case of acute myeloid leukemia with a t(X;21)(q25-26;q22).

Steven D P Moore1, Onyinye Offor, Judith A Ferry, Philip C Amrein, Cynthia C Morton, Paola Dal Cin.   

Abstract

We report a novel chromosomal translocation in AML, t(X;21)(q25-26;q22), resulting in a fusion transcript between two ETS domain family members, ELF4 (at Xq25) and ERG (at 21q22). ERG has been associated previously with other fusion partners, specifically FUS and EWSR1, and implicated in both AML and Ewing's sarcoma. RT-PCR analysis of RNA isolated from bone marrow samples from the patient demonstrates that the translocation occurs within intron 1 of ERG isoform 1 (ERG-1) and intron 2 of ELF4 resulting in an in-frame fusion joining exon 2 from ELF4 with exon 2 of ERG. This is the first reported case of an ELF4-ERG fusion and identification of the specific ERG exon involved in the fusion that differentiates ERG isoforms. In addition, this case also directly implicates a new role for ELF4 in cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16303180     DOI: 10.1016/j.leukres.2005.10.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

Review 1.  The oncogenic role of the ETS transcription factors MEF and ERG.

Authors:  Goro Sashida; Elena Bazzoli; Silvia Menendez; Yan Liu; Stephen D Nimer
Journal:  Cell Cycle       Date:  2010-09-13       Impact factor: 4.534

2.  The transcription factor E74-like factor controls quiescence of endothelial cells and their resistance to myeloablative treatments in bone marrow.

Authors:  Mariela Sivina; Takeshi Yamada; Chun Shik Park; Monica Puppi; Suleyman Coskun; Karen Hirschi; H Daniel Lacorazza
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-02-24       Impact factor: 8.311

Review 3.  Is it important to decipher the heterogeneity of "normal karyotype AML"?

Authors:  Stephen D Nimer
Journal:  Best Pract Res Clin Haematol       Date:  2008-03       Impact factor: 3.020

4.  Integration of Elf-4 into stem/progenitor and erythroid regulatory networks through locus-wide chromatin studies coupled with in vivo functional validation.

Authors:  Aileen M Smith; Fernando J Calero-Nieto; Judith Schütte; Sarah Kinston; Richard T Timms; Nicola K Wilson; Rebecca L Hannah; Josette-Renee Landry; Berthold Göttgens
Journal:  Mol Cell Biol       Date:  2011-12-12       Impact factor: 4.272

Review 5.  Roles and regulations of the ETS transcription factor ELF4/MEF.

Authors:  Mary Ann Suico; Tsuyoshi Shuto; Hirofumi Kai
Journal:  J Mol Cell Biol       Date:  2017-06-01       Impact factor: 6.216

Review 6.  Targeting Transcription Factors for Cancer Treatment.

Authors:  Mélanie Lambert; Samy Jambon; Sabine Depauw; Marie-Hélène David-Cordonnier
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411

7.  Hyper-SUMOylation of ERG Is Essential for the Progression of Acute Myeloid Leukemia.

Authors:  Xu Chen; Yuanyuan Qin; Zhenzhen Zhang; Zhengcao Xing; Qiqi Wang; Wenbin Lu; Hong Yuan; Congcong Du; Xinyi Yang; Yajie Shen; Biying Zhao; Huanjie Shao; Xiaotong Wang; Hongmei Wu; Yitao Qi
Journal:  Front Mol Biosci       Date:  2021-03-26

8.  Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines.

Authors:  Raja Nhili; Paul Peixoto; Sabine Depauw; Sébastien Flajollet; Xavier Dezitter; Manoj M Munde; Mohamed A Ismail; Arvind Kumar; Abdelbasset A Farahat; Chad E Stephens; Martine Duterque-Coquillaud; W David Wilson; David W Boykin; Marie-Hélène David-Cordonnier
Journal:  Nucleic Acids Res       Date:  2012-10-23       Impact factor: 16.971

9.  Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer.

Authors:  Liqiang Xi; Andrew Feber; Vanita Gupta; Maoxin Wu; Andrew D Bergemann; Rodney J Landreneau; Virginia R Litle; Arjun Pennathur; James D Luketich; Tony E Godfrey
Journal:  Nucleic Acids Res       Date:  2008-10-16       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.